Quidel

News Release

Printer Friendly Version View printer-friendly version << Back
October 25, 2001 at 6:29 PM EDT

Quidel *Third Quarter Conference Call Alert*

SAN DIEGO, Oct 25, 2001 /PRNewswire via COMTEX/ -- Quidel Corporation (Nasdaq: QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, today announced that it will release 2001 third quarter results after market close on Thursday, November 1, at 4:10 p.m. Eastern Time (1:10 p.m. Pacific Time).

Andre de Bruin, Executive Chairman, S. Wayne Kay, President and Chief Executive Officer, and Paul Landers, Chief Financial Officer, will be hosting an investment-community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Thursday, November 1, 2001 to discuss those results and to answer questions.

Individuals interested in participating in the conference call may do so by calling (800) 633-8682 or via the Internet at www.quidel.com. To listen to the live call, please go to the Web site 10 minutes prior to its start to register, download, and install the necessary audio software.

A replay will be available on Quidel's Web site for 14 days. A telephone replay will also be available for 48 hours following the conclusion of the call by dialing (800) 633-8284, and entering reservation number 19907666.

About Quidel

Quidel Corporation discovers, develops, manufactures and markets rapid point-of-care diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions associated with women's health, in areas such as reproduction and diseases of the elderly. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia, infectious mononucleosis and bacterial vaginosis. Quidel's products are sold to healthcare professionals for use in physicians' offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information to enable rapid treatment and improve health outcomes, lower costs and increase patient satisfaction. For more information, please visit Quidel's Web site at www.quidel.com.

SOURCE Quidel Corporation

CONTACT:
Bruce Voss, bvoss@lhai.com, or Martin Halsall,
mhalsall@lhai.com, both of Lippert/Heilshorn & Associates, +1-310-691-7100,
for Quidel Corporation;
or Andrea Wasilew, Manager of Investor Relations,
+1-858-552-7955, ir@quidel.com, or Paul E. Landers, Vice President & CFO,
+1-858-552-7962, both of Quidel Corporation